Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
This study is currently recruiting participants.
This research study is evaluating a drug called carfilzomib used in combination with another drug called belinostat with participants who have relapsed or refractory non-Hodgkin lymphoma (NHL).
Study Type: Interventional
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study
Diffuse Large B-cell Lymphoma
Mantle Cell Lymphoma
Peripheral T-cell Lymphoma
Phase: Phase 1
External Link: https://clinicaltrials.gov/ct2/show/NCT02142530